Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period.
about
HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa.Decreased emergence of HIV-1 drug resistance mutations in a cohort of Ugandan women initiating option B+ for PMTCT.HIV diversity and drug resistance from plasma and non-plasma analytes in a large treatment programme in western Kenya.Antiretroviral treatment failure, drug resistance, and subtype diversity in the only pediatric HIV clinic in Rhode Island.Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial.Low-Frequency Drug Resistance in HIV-Infected Ugandans on Antiretroviral Treatment Is Associated with Regimen Failure.Non-R5-tropic HIV-1 in subtype A1 and D infections were associated with lower pretherapy CD4+ cell count but not with PI/(N)NRTI therapy outcomes in Mbarara, UgandaInfecting HIV-1 Subtype Predicts Disease Progression in Women of Sub-Saharan Africa.Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial.Design, Synthesis, and Biological Evaluation of Novel Benzoyl Diarylamine/ether Derivatives as Potential Anti-HIV-1 Agents.Sensitive detection of HIV-1 resistance to Zidovudine and impact on treatment outcomes in low- to middle-income countries.Absence of HIV-1 drug resistance mutations supports the use of dolutegravir in Uganda.
P2860
Q33669836-08224C9A-8300-4659-97C3-CE778D04F156Q33745946-CA5CB7CB-5486-41E8-9D4E-8330D8560CF6Q34549498-5A1241E1-B804-4B3B-909C-1A6AE9C48DB8Q35555200-4224EC2F-A655-4B29-9F5C-3C8CFFAA2F88Q35588149-AD6A4521-FC66-46E8-B73C-C7C3EFF7F0DFQ36933330-9A4543F2-426D-484E-8B1A-3050BBF70FA5Q37048027-63C209CA-6887-47B3-9A00-EEF431A03E3CQ37604707-38769915-738F-49C6-91B7-0024EFA70F4EQ38791126-ABED883B-0D46-4941-8EF6-D5CDC2393B3CQ38928255-9A8A6770-87BE-4F71-8078-92A706284B04Q46499496-46D9BE04-130E-4E09-AF2E-A1FD5DA5B521Q47558450-350876C0-B289-4B83-8A69-B73E22EFDDFF
P2860
Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Treatment failure and drug res ...... s over a 10-year study period.
@ast
Treatment failure and drug res ...... s over a 10-year study period.
@en
type
label
Treatment failure and drug res ...... s over a 10-year study period.
@ast
Treatment failure and drug res ...... s over a 10-year study period.
@en
prefLabel
Treatment failure and drug res ...... s over a 10-year study period.
@ast
Treatment failure and drug res ...... s over a 10-year study period.
@en
P2093
P2860
P1433
P1476
Treatment failure and drug res ...... s over a 10-year study period.
@en
P2093
Cissy Kityo
Denis M Tebit
Emmanuel Ndashimye
Fred Kyeyune
Immaculate Nankya
JCRC Drug Resistance Working Group
Juliet Akao
Peter Mugyenyi
Robert A Salata
P2860
P304
P356
10.1097/QAD.0B013E3283610EC7
P407
P577
2013-07-01T00:00:00Z